OM
CRDF icon

Opaleye Management’s Cardiff Oncology CRDF Stock Holding History

Opaleye Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-463,000
Closed -$3.08M – 50
2021
Q2 		$3.08M Sell
463,000
-113,000
-20% -$958K 0.51% 42
2021
Q1 		$5.33M Sell
576,000
-1,086,500
-65% -$13.2M 0.78% 38
2020
Q4 		$29.9M Sell
1,662,500
-69,100
-4% -$1.21M 3.91% 6
2020
Q3 		$24.6M Buy
1,731,600
+1,141,600
+193% +$7.54M 4.81% 4
2020
Q2 		$2.96M Buy
+590,000
New +$1.21M 0.6% 41

Other funds holding CRDF

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Opaleye Management's CRDF Position: Q3 2021 in Review

Opaleye Management sold out of Cardiff Oncology (CRDF) in Q3 2021, closing a stake of 463,000 shares — an estimated $3.08M sold.

Opaleye Management first reported a position in CRDF in Q2 2020 and held it in 5 quarters. The position peaked at $29.9M in Q4 2020. 94 funds tracked by Wall St. Rank hold CRDF as of Q3 2021.

  • Opaleye Management reported no remaining Cardiff Oncology position as of Q3 2021 after selling out during the quarter.
  • Opaleye Management sold 463,000 Cardiff Oncology shares in Q3 2021, an estimated $3.08M.
  • Opaleye Management first reported a position in Cardiff Oncology in Q2 2020 and held it in 5 quarters.
  • Opaleye Management's Cardiff Oncology position peaked at $29.9M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2021.

Based on Opaleye Management's 13F filing for Q3 2021, filed 16 Nov 2021.